Tenax’s TNX-103 Misses Primary Endpoint in Late-Stage Heart Failure Trial
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
/ 2 items
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
Cantor Fitzgerald initiates Overweight on Tenax Therapeutics with $35 target. Under-the-radar biotech nears Q3 2026 Phase 3 readout for potential first PH-HFpEF therapy — high-risk, high-reward setup.